Live Quote · OTCGNBTHealthcare· Biotechnology

Generex Biotechnology Corporation

$0.00 0.00%(+$0.00)
TickerSpark Score
43/100
Weak
80
Valuation
60
Profitability
10
Growth
36
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNBT research report →

52-Week Range0% of range
Low
$0.00
Current
$0.00
High
$0.14
Company Overviewgenerex.com/index.html

About the company

Founded in 1983 and headquartered in Miramar, Florida, Generex Biotechnology Corporation initially specialized in the delivery of large molecule drugs into the oral cavity via a portable aerosol applicator for use in Canada and the United States, notably offering Generex Oral-lyn, an oral insulin product. The company also had a significant focus on oncology, developing AE37, a synthetic peptide vaccine that had completed Phase IIb clinical trials aimed at stimulating a potent and specific immune response against HER-2/neu oncogenes in breast and prostate cancer patients. Beyond therapeutics, Generex was involved in the development, manufacturing, and distribution of rapid point-of-care in-vitro medical diagnostics for a spectrum of infectious diseases, including HIV, tuberculosis, malaria, and hepatitis, providing both test kits and cassettes.

CEO
Joseph Moscato
IPO
1998
Employees
15
HQ
Miramar, FL, US

Price Chart

-99.82% · this period
$0.54$0.27$0.00May 17Jan 31Oct 27
Valuation
Market Cap
$0
P/E
-0.00
P/S
0.00
P/B
-0.00
EV/EBITDA
-0.43
Div Yield
0.00%
Profitability
Gross Margin
78.24%
Op Margin
-673.54%
Net Margin
-1252.72%
ROE
216.76%
ROIC
-88.91%
Growth & Income
Revenue
$2.66M · -57.11%
Net Income
$-33,335,000 · -256.87%
EPS
$-0.46 · -228.57%
Op Income
$-17,923,000
FCF YoY
38.06%
Performance & Tape
52W High
$0.14
52W Low
$0.00
50D MA
$0.00
200D MA
$0.01
Beta
-0.06
Avg Volume
18.59K

Get TickerSpark's AI analysis on GNBT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 27, 19Prioletti Mark Joseph SEother0
May 14, 19Salvo Lawrence Anthony Srother0
Dec 4, 18Haines Harold Graybuy945
Dec 4, 18Haines Harold Graybuy555
Dec 7, 18Haines Harold Graybuy8,000
Dec 7, 18Haines Harold Graybuy300
Oct 3, 18Ro Andrewother4,500
Oct 3, 18Purcell Richard David Jr.other4,500
Oct 3, 18MCGEE BRIANother1,000
Oct 3, 18Lyman Gary Herbertother1,000
Coverage · GNBT

Our GNBT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on GNBT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate GNBT report →
Internal Compare

Similar companies

Peers in the same neighborhood.